U.S., Sept. 18 -- An application to own the trademark for 'KALSTEDI' has been filed on Jun. 26, 2025.
Owner(s):
Bridgebio Pharma, Inc.; 3160 Porter Drive, Suite 250, , CALIFORNIA
Goods and/or Services:
For: Pharmaceutical preparations for the treatment of endocrine and respiratory diseases and disorders, including autosomal dominant hypocalcemia type 1, hypoparathyroidism, and eosinophilic asthma
Class(es): 005, 006, 018, 044, 046, 051, 052
Mark Drawing Type: 4 - STANDARD CHARACTER MARK
https://eog-tmng.uspto.gov/#/issueDate=2025-09-16&serialNumber=99255444
Disclaimer: Curated by HT Syndication....